{
    "clinical_study": {
        "@rank": "90836", 
        "acronym": "LOGIC-2", 
        "arm_group": [
            {
                "arm_group_label": "Nurse-directed", 
                "arm_group_type": "Active Comparator", 
                "description": "Blood glucose control guided by paper protocol"
            }, 
            {
                "arm_group_label": "LOGIC-Insulin", 
                "arm_group_type": "Experimental", 
                "description": "Blood glucose control guided by the LOGIC-Insulin algorithm"
            }
        ], 
        "brief_summary": {
            "textblock": "Most critically ill patients are confronted with hyperglycaemia, which is associated with an\n      increased mortality and morbidity risk. Normalising these elevated blood glucose levels by\n      intensive insulin therapy may improve patient outcome, but is associated with an increased\n      risk of hypoglycaemia. The LOGIC-2 study hypothesises that the LOGIC-Insulin computerised\n      software algorithm will allow better (less hyperglycaemia) and safer (less hypoglycaemia)\n      blood glucose control in critically ill patients than nurse-directed blood glucose control."
        }, 
        "brief_title": "Multicentre LOGIC-Insulin Algorithm-guided Versus Nurse-directed Blood Glucose Control During Critical Illness (LOGIC-2)", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Critical Illness", 
            "Hyperglycemia", 
            "Hypoglycemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Critical Illness", 
                "Hyperglycemia", 
                "Hypoglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients admitted to the ICU with an expected stay of at least 48 hours and already\n             receiving or potentially needing insulin infusion for blood glucose control. These\n             patients should already have or need an arterial and central venous line\n\n          -  Patients should be 18 years or older\n\n        Exclusion Criteria:\n\n          -  Not critically ill\n\n          -  Age under 18 years\n\n          -  Patients already enrolled in another intervention randomized controlled trial\n\n          -  Patients expected to die within 12 hours (=moribund patients)\n\n          -  No arterial line or central venous line needed\n\n          -  Pregnancy or lactating\n\n          -  Patients suffering from ketoacidotic or hyperosmolar coma on admission\n\n          -  Patients who have been previously been included in the LOGIC-2 study\n\n          -  Allergy to insulin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1550", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02056353", 
            "org_study_id": "LOGIC-Insulin 2.1.1", 
            "secondary_id": [
                "ML9517", 
                "S55613", 
                "80M0563", 
                "IWT-TBM 100793"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "LOGIC-Insulin", 
                "intervention_name": "LOGIC-Insulin algorithm", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Nurse-directed", 
                "intervention_name": "Paper protocol", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Software", 
            "Algorithm", 
            "Cardiac surgery"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jasperina.dubois@jessazh.be", 
                    "last_name": "Jasperina Dubois, MD", 
                    "phone": "32-11-308971"
                }, 
                "facility": {
                    "address": {
                        "city": "Hasselt", 
                        "country": "Belgium", 
                        "zip": "3500"
                    }, 
                    "name": "Jessa Hospital"
                }, 
                "investigator": {
                    "last_name": "Jasperina Dubois, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dieter.mesotten@med.kuleuven.be", 
                    "last_name": "Dieter Mesotten, MD, PhD", 
                    "phone": "32-16-344021"
                }, 
                "contact_backup": {
                    "email": "tom.vanherpe@esat.kuleuven.be", 
                    "last_name": "Tom Van Herpe, Eng, PhD", 
                    "phone": "32-16-340987"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Dept Intensive Care Medicine, University Hospitals Leuven"
                }, 
                "investigator": [
                    {
                        "last_name": "Dieter Mesotten, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Greet Van den Berghe, MD, PhD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alexander.wilmer@uzleuven.be", 
                    "last_name": "Alexander Wilmer, MD, PhD"
                }, 
                "contact_backup": {
                    "email": "joost.wauters@uzleuven.be", 
                    "last_name": "Joost Wauters, MD, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Medical Intensive Care, University Hospitals Leuven"
                }, 
                "investigator": {
                    "last_name": "Alexander Wilmer, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marcus.j.schultz@gmail.com", 
                    "last_name": "Marcus Schultz, MD, PhD"
                }, 
                "contact_backup": {
                    "email": "r.t.vanhooijdonk@amc.uva.nl", 
                    "last_name": "Roosmarijn van Hooijdonk, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105"
                    }, 
                    "name": "Academic Medical Center (AMC)"
                }, 
                "investigator": {
                    "last_name": "Marcus Schultz, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "LOGIC-Insulin Computerized Algorithm-guided Versus Nurse-directed Blood Glucose Control in Critically Ill Patients: the LOGIC-2 Multicentre Randomized Controlled Trial", 
        "overall_contact": {
            "email": "dieter.mesotten@med.kuleuven.be", 
            "last_name": "Dieter Mesotten, MD, PhD", 
            "phone": "32-16-344021"
        }, 
        "overall_contact_backup": {
            "email": "tom.vanherpe@esat.kuleuven.be", 
            "last_name": "Tom Van Herpe, Eng, PhD", 
            "phone": "32-16-340987"
        }, 
        "overall_official": [
            {
                "affiliation": "Katholieke Universiteit Leuven", 
                "last_name": "Dieter Mesotten, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Katholieke Universiteit Leuven", 
                "last_name": "Greet Van den Berghe, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Jessa Hospital Hasselt", 
                "last_name": "Jasperina Dubois, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "last_name": "Marcus Schultz, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Belgium: Ethics Committee", 
                "Netherlands: Medical Ethics Review Committee (METC)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adequacy of reaching and maintaining the target range for blood glucose during the intervention (Effectiveness of glycaemic control)", 
            "measure": "Glycemic Penalty Index (GPI) during the Intervention", 
            "safety_issue": "No", 
            "time_frame": "up to 14 days post-randomization"
        }, 
        "reference": [
            {
                "PMID": "22961576", 
                "citation": "Van Herpe T, Mesotten D, Wouters PJ, Herbots J, Voets E, Buyens J, De Moor B, Van den Berghe G. LOGIC-insulin algorithm-guided versus nurse-directed blood glucose control during critical illness: the LOGIC-1 single-center, randomized, controlled clinical trial. Diabetes Care. 2013 Feb;36(2):188-94. doi: 10.2337/dc12-0584. Epub 2012 Sep 6."
            }, 
            {
                "PMID": "18302732", 
                "citation": "Van Herpe T, De Brabanter J, Beullens M, De Moor B, Van den Berghe G. Glycemic penalty index for adequately assessing and comparing different blood glucose control algorithms. Crit Care. 2008;12(1):R24. Epub 2008 Feb 26."
            }, 
            {
                "PMID": "19531590", 
                "citation": "Van den Berghe G, Schetz M, Vlasselaers D, Hermans G, Wilmer A, Bouillon R, Mesotten D. Clinical review: Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J Clin Endocrinol Metab. 2009 Sep;94(9):3163-70. Epub 2009 Jun 16. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02056353"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Katholieke Universiteit Leuven", 
            "investigator_full_name": "Greet Van den Berghe", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of patients to have had one or more episodes of severe hypoglycaemia (<40 mg/dL) during the intervention", 
                "measure": "Proportion of Patients With Severe Hypoglycaemia (<40 mg/dL) during the Intervention", 
                "safety_issue": "Yes", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "Number of severe hypoglycaemic values as a fraction of all blood glucose measurements during the intervention", 
                "measure": "Incidence of Severe Hypoglycemia (<40 mg/dL) during the Intervention", 
                "safety_issue": "Yes", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "Mean and median arterial blood glucose level", 
                "measure": "Blood Glucose Level Per Treatment Group during the Intervention", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "Adequacy of reaching and maintaining the target range for blood glucose, as assessed by the Hyperglycaemic index (HGI)", 
                "measure": "Hyperglycaemic index (HGI)", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "measure": "Time in target range", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "measure": "Time to target range", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "marker of blood glucose fluctuations", 
                "measure": "Daily maximal blood glucose difference", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "Number of mild hypoglycaemic values as a fraction of all blood glucose measurements during the intervention", 
                "measure": "Incidence of mild hypoglycaemia (blood glucose level < 70 mg/dL or 3.9 mmol/L) during the Intervention", 
                "safety_issue": "Yes", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "Proportion of patients to have had one or more episodes of mild hypoglycaemia during the intervention", 
                "measure": "Proportion of Patients With Mild Hypoglycaemia (blood glucose level < 70 mg/dL or 3.9 mmol/L) during the Intervention", 
                "safety_issue": "Yes", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "marker of workload", 
                "measure": "Interval between blood glucose measurements", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "the number and proportion of patients in which the LOGIC-Insulin was not followed for a time period of at least 8 hours, which is the duration of one nurse shift.", 
                "measure": "Protocol compliance in the intervention group", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "the number and proportions of recommendations by the software that were overruled by the bed-side nurses\nMinor overrules: absolute insulin dose difference of >0.1 and < 1IU/h\nMajor overrules: absolute insulin dose difference of >= 1IU/h\nMajor overrules will also be qualitatively assessed", 
                "measure": "Overrules in the intervention group", 
                "safety_issue": "Yes", 
                "time_frame": "up to 14 days post-randomization"
            }, 
            {
                "description": "The diagnosis of \"new infection\" will be based on the administration of antibiotics, beyond the prophylactic scope", 
                "measure": "Incidence of new infections in the ICU", 
                "safety_issue": "No", 
                "time_frame": "up to 90 days post-randomization"
            }, 
            {
                "measure": "Length of stay in the ICU", 
                "safety_issue": "No", 
                "time_frame": "up to 90 days post-randomization"
            }, 
            {
                "measure": "Length of stay in the hospital", 
                "safety_issue": "No", 
                "time_frame": "up to 90 days post-randomization"
            }, 
            {
                "measure": "Mortality in the ICU", 
                "safety_issue": "Yes", 
                "time_frame": "up to 90 days post-randomization"
            }, 
            {
                "measure": "Mortality in the hospital", 
                "safety_issue": "Yes", 
                "time_frame": "up to 90 days post-randomization"
            }, 
            {
                "measure": "Landmark 90-day mortality", 
                "safety_issue": "Yes", 
                "time_frame": "up to 90 days post-randomization"
            }, 
            {
                "measure": "All direct medical costs from a healthcare payer's perspective", 
                "safety_issue": "No", 
                "time_frame": "up to 90 days post-randomization"
            }, 
            {
                "description": "EuroQol-5D", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "up to 90 days post-randomization"
            }
        ], 
        "source": "Katholieke Universiteit Leuven", 
        "sponsors": {
            "collaborator": {
                "agency": "Agentschap voor Innovatie door Wetenschap en Technologie", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Katholieke Universiteit Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}